JATT Ventures III

JATT Ventures is a life sciences-focused venture capital and incubation firm that specializes in identifying and developing high-potential biotechnology assets. The firm is led by a team of experienced industry professionals, including Dr. Someit Sidhu, and is known for its strategic use of Special Purpose Acquisition Companies (SPACs) to facilitate the public listing of innovative biotech companies. A primary example of their model is JATT Acquisition Corp, which merged with Zura Bio to advance a pipeline of immunology-focused therapies. Through its various entities, including JATT Ventures III, the firm provides capital, operational expertise, and scientific guidance to its portfolio companies. Their current focus includes clinical-stage assets targeting immunology and inflammation, such as ZB-168 and ZB-880. JATT Ventures aims to accelerate the delivery of transformative medicines by bridging the gap between early-stage development and public market access.